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lymphocyte recovery and transplant outcomes in 78 paients
with MDS and AML evolving from MDS receiving T-cell-
repleted transplantation from an haploidentical related
donors. The median patient follow-up was 510 days (range,
15-3419 days). Higher relapse rate was observed in patients
with an day 30 absolute lymphocyte count (ALC-30) < 300
cells/mL compared to patients with an ALC-30  300 cells/mL
(35.5% vs. 13.8%, P¼0.049). More patients had bacteria
infections in those with an ALC-30 < 300 cells/mL compared
with patients with an ALC-30  300 cells/mL (25.8% vs. 3.4%,
P¼0.015). In multivariate analysis, patients with a higher
the ALC-30 (300 cells/mL) had improved overall survival (HR
0.099, 95% CI 0.029-0.337; P<0.0001), leukemia free
survival (HR 0.271, 95% CI 0.122-0.602; P<0.0001), less
relapse (HR 0.096 95% CI 0.011-0.827; P¼0.033), and less
transplant-related mortality (TRM, HR¼0.073; 95% CI 0.016-
0.324; P¼0.001). A three human leukocyte antigen loci
mismatch was associated with a higher incidence of TRM
(HR 5.026 95% CI 1.392-18.173; P¼0.014). Our results
suggest that a higher ALC-30 ( 300 cells/mL) could be
a useful and simple tool to predict MDS and AML evolving
from MDS patients with a superior outcome after unma-
nipulated HBMT.Immune reconstitution studies following early alemtuzumab-based RIC HSCT
IR evaluated in 66 patients with data for
 2 time points
3 months 6 months 12 months
MRD MUD MRD MUD MRD MUD
ALC (cells/cumm) 1044 593* 1488 1011@ 2338 1695
CD3 (cells/cumm) 478 195
ˇ
1250 1016 1306 1116
CD4 (cells/cumm) 169 69# 565 605 770 649
CD8 (cells/cumm) 278 123# 495 386 565 440
CD16+56 (cells/cumm) 183 166 180 181 216 102
CD19 (cells/cumm) 381 37$ 498 50$ 739 175$
IgA (mg/dL) 49 35 58 34 73 44+
IgM (mg/dL) 41 25 61 59 66 47
PHA (% normal) 18% 33.9% 42.9% 44.6% 80.5% 95.0%
Infections (total
number
in all 106 patients)
Bacterial 132 69 45
Viral 106 51 37
Fungal 15 10 14
Time 3 months 3 months 6 months
Lymphocyte numbers, immunoglobulin levels and PHA proliferation are reported as median values. Infections are reported as total number of occurrences for all
patients during that time period and include both localized and systemic episodes.
@ P ¼ .03.
+ P ¼ .02.
ˇ
P ¼ .005.
* P ¼ .001.
# P ¼ .01.
$ P  .0001.177
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Cord blood transplant (CBT) recipients are at increased
risk of transplant related mortality, in part due to delayedhematopoietic and immune system recovery resulting in
increased infectious complications. However, without direct
clinical measures of immunocompetence, the speciﬁc role of
delayed immunity on CBT outcomes is not easily determined
and intervention studies not possible.
Blood samples were collected (pre-transplant and at days
28, 56, 100, 180 and 365 post-transplant) in 34 consecutive
patients undergoing myeloablative CBT for treatment of
hematologic malignancies. All samples were subjected to
Immunoseq, a novel T cell receptor (TCR) sequencing assay
that delivers an unprecedented depth of sequencing data.
From these data, clonal expansion and contraction of
hundreds of thousands of clones were tracked over time and
TCR diversity was directly measured. Basic clinical outcomes
for all patients were also determined, including GvHD,
overall survival, disease free survival, regimen related
toxicities and infectious complications.
The ability to track clones demonstrated tremendous
oscillation, with an almost entirely new T cell repertoire
appearing at least monthly in CBT recipients. Furthermore, in
contrast to healthy controls whose blood was sampled on
a similar time-course, where themost frequent Tcell clone at
one time point remains the top clone at subsequent timepoints, the largest clones observed early post-transplant in
CBT recipients subsequently dropped below detectionwithin
weeks of direct measurement. Of the 34 patients studied, six
died of infectious complications between day 100 and one
year. Notably, TCR diversity values for these six patients were
far lower than those of the remaining patients (P-value ¼
0.015, see Figure 1).
The TCR repertoire is exceptionally dynamic following
CBT, with many T cell clones rising to high frequency and
then receding to an undetectably low level in a matter of
weeks. By two months after transplant, TCR diversity accu-
rately predicted risk of death due to infection in this patient
cohort, suggesting that diversity of the TCR is a direct
measure of immunocompetence and may be useful as a test
Table 1
Effect of Statin on Immunomes
Statin vs.
non-statin
D30 (%)
P-value Median(Range)
Non-statin
exposed
Median(Range)
Statin exposed
Absolute
Lymphocyte
count
0.04688 850 (100-1300) 774.8 (109-2120)
DR+/14+ (absolute) 0.375 77.6 (43.1-86.3) 69.3 (19.2-92.1)
DR-/14+ (absolute) 0.1094 12.5 (2.7-34.4) 25.4 (1.8-78.6)
CD3+/56-/16- 0.04688 55 (15.4-78.2) 78.7 (52.5-95.8)
CD19+ 1 1 (0.2-2.0) 0.7 (0-39.4)
CD69 +/CD3+ 0.8655 3.2 (0.7-4.7) 2.7 (1.1-4.4)
CD3+/DR+ 1 5 (1.4-30.1) 5.1 (0.4-13.7)
CD3+/DR - 0.1563 48 (17.5-77.1) 70.1 (52.9-85.1)
CD3-/56+/16+ 0.03125 33.5 (16.5-42.2) 7.9 (2.7-21.0)
CD3-/56+/16+/314+ 0.03125 18.1 (6.5-34.0) 4.6 (0.7-10)
CD3-/56+/16+/117- 0.03125 22.4 (11.8-36.4) 6.3 (0.9-12.9)
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congenital immunosuppression.
Figure 1. TCR Repertoire Size: NRM v. other patients
The ﬁgure shows a comparison of TCR repertoire size, estimated based on
high-throughput sequencing of TCRb rearrangements, for all surviving
patients (N is indicated below each panel) with and without eventual non-
relapse mortality (NRM). TCR repertoire size values are given as quartiles for
both populations, with whiskers representing the maximum and minimum
values. Signiﬁcance is assessed using a one-tailed Mann-Whitney U test;
patients who went on to suffer from non-relapse mortality had signiﬁcantly
lower estimated repertoire sizes at 56 and 100 days post-transplant.
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Introduction: Acute graft-versus-host-disease (aGVHD) is
a frequent and lethal complication of HSCT despite current
prophylaxis. Release of pro-inﬂammatory cytokines lead to
damage of host tissues. Statins have been shown to reduce
pro-inﬂammatory cytokines while increasing the migration
of anti-inﬂammatory cytokines, especially when donor and
recipient are exposed to it, thus reducing aGVHD. We
present data on 14 patients enrolled in an ongoing phase II
study evaluating the efﬁcacy of atorvastatin as aGVHD
prophylaxis in patients undergoing matched-related donor
AHSCT.Method: In this phase II study donors receive atorvastatin 40
mg daily for at least 14 days before leukapheresis. Recipient
patients receive Atorvastatin 40mg daily starting at least 7
days before initiation of transplant conditioning regimen in
addition to standard approved GVHD prophylaxis with
tacrolimus and methotrexate. Atorvastatin is continued until
development of grade II or higher aGVHD, cessation of
aGVHD prophylaxis and or adverse event. We compared the
immune reconstitution pattern of patients on statin to those
of historic control patients not on statin matched to age, sex,
type of AHSCT and intensity of regimen.
Result: Median age of patients is 47 (range 27-67) and of
donor 46.5 (29-64). Ten patients received reduced intensity
AHSCT. Median neutrophil and platelets engraftment were
18.9 and 12.9 days. With a median follow up of 120 days (23-
287), two patients have relapsed one of whom died due to
disease. The median day 30 CD3 and CD34 chimerism were
81% and 100%. Two patients (14%) have developed grade II
aGVHD with no patients developing grade III or IV aGVHD.
Two patients developed chronic GVHD both mild and
limited. At day 30 post HSCT, compared to historic control,
patients exposed to statin had no difference in B cells(CD19+)
or total T cells (CD3+/DR+; CD3+/DR-), but a signiﬁcant
decline in NK cells, including total NK cells and NK cells
positive for CD314 (Table 1).
Conclusion: While this is a small sample, and no conclusion
can be deduced, it is interesting to note the signiﬁcant
difference in the number of NK cells in patients exposed to
statin as compared to historic control.179
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